Jon Salmanton-García, Francesco Marchesi, Philipp Koehler, Barbora Weinbergerová, Natasa Čolović, Iker Falces-Romero, Caterina Buquicchio, Francesca Farina, Jens VAN Praet, Monika M Biernat, Federico Itri, Lucia Prezioso, Carlo Tascini, Antonio Vena, Alessandra Romano, Mario Delia, Julio Dávila-Valls, Sonia Martín-Pérez, Esperanza Lavilla-Rubira, Tatjana Adžić-Vukičević, Daniel García-Bordallo, Alberto López-García, Mariana Criscuolo, Verena Petzer, Nicola S Fracchiolla, Ildefonso Espigado, Uluhan Sili, Stef Meers, Nurettin Erben, Chiara Cattaneo, Athanasios Tragiannidis, Eleni Gavriilaki, Martin Schönlein, Mirjana Mitrovic, Nikola Pantic, Maria Merelli, Jorge Labrador, José-Ángel Hernández-Rivas, Andreas Glenthøj, Guillemette Fouquet, Maria Ilaria Del Principe, Michelina Dargenio, María Calbacho, Caroline Besson, Milena Kohn, Stefanie Gräfe, Ditte Stampe Hersby, Elena Arellano, Gökçe MelisÇOLAK, Dominik Wolf, Monia Marchetti, Anna Nordlander, Ola Blennow, Raul Cordoba, Bojana Mišković, Miloš Mladenović, Martina Bavastro, Alessandro Limongelli, Laman Rahimli, Livio Pagano, Oliver A Cornely
INTRODUCTION: Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections, which reduce both hospitalization and mortality rates. Nirmatrelvir/ritonavir was authorised in Europe in December 2021, while molnupiravir is not yet licensed in Europe as of February 2022. Molnupiravir may be an alternative to nirmatrelvir/ritonavir, because it displays less frequent drug-drug interactions and contraindications. A caveat connected to molnupiravir derives from the mode of action inducing viral mutations...
August 13, 2023: International Journal of Antimicrobial Agents